Antengene, LegoChem draft antibody-drug conjugate deal

2021-10-26

LegoChem Biosciences and Antengene will partner for a Research Collaboration and License Option Agreement focused on new antibody-drug conjugates. Together the companies will generate and assess ADC candidates utilizing LCB's ADC technology platform and Antengene's antibodies aside from an exclusive option for global licensing rights by Antengene for ADC candidates developed and commercialized as a result of their collaboration.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.